Covid infects biopharma’s biggest sellers

It takes phenomenal revenues to win a place among biopharma’s biggest-selling drugs, and not many franchises are likely ever to amass more than $100bn in lifetime sales. Remarkably, 15 products are set to achieve this.

And there are a couple of new arrivals since the last time Evaluate Vantage ran these numbers, in mid-2019. Biontech and Pfizer’s Comirnaty is the most notable addition, considering the short amount of time it will have taken to generate these sales. With the outlook for Covid-related products still highly unpredictable this vaccine could yet climb the rankings, and other pandemic projects might also make appearances.